For research use only. We do not sell to patients.
SCH 546738
CAS No. : 906805-42-3
Biological Activity：SCH 546738 is a potent, orally active and non-competitive CXCR3 antagonist, the affinity constant (Ki) of SCH 546738 binding to human CXCR3 receptor is determined to be 0.4 nM in multiple experiments.
Research Area：Inflammation/Immunology|Endocrinology
Targets：CXCR
Related Screening Libraries:Bioactive Compound Library Plus;GPCR/G Protein Compound Library;Immunology/Inflammation Compound Library;Small Molecule Immuno-Oncology Compound Library;Endocrinology Compound Library;Targeted Diversity Library;Chemokine Compound Library;
Related Small Molecules:Nicotinamide N-oxide;FC131;CXCR4 antagonist 2;AMG 487 (S-enantiomer);CXCR4 antagonist 6;CXCR2 antagonist 4;VUF11207 fumarate;KRH-3955 hydrochloride;IT1t dihydrochloride;NBI-74330;MSX-130;Elubrixin;CXCR2 antagonist 2;CXCR2-IN-1;Mavorixafor;HF51116;Reparixin L-lysine salt;HF50731;AZD-5069;AZD8797;BAM-12P;CTCE-0214;Baohuoside I;Ladarixin sodium;CXCR2 antagonist 3
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides
About Us:
- MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use；
- Structurally and synthetically diverse biologically active compounds；
- roduct quality is the key to our success and we take pride in offering only the highest-grade products.；
- We provide HNMR, LC-MS, HPLC, stability testing and activity assays of our products to clients.；
- Product identity, quality, purity and activity are assured by our robust quality control programs and procedures.；
- Customized order volume ranging from milligrams to kilograms scale；
Structurally and synthetically diverse biologically active compounds；
We provide customer-oriented services. To explore more, please contact us at [email protected]. Our team will gladly assist you.
